Medpace (NASDAQ:MEDP) and Bioanalytical Systems (NASDAQ:BASI) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, dividends, analyst recommendations and valuation.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Medpace and Bioanalytical Systems, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Medpace 0 4 3 0 2.43
Bioanalytical Systems 0 0 0 0 N/A

Medpace currently has a consensus target price of $42.83, suggesting a potential downside of 22.74%. Given Medpace’s higher possible upside, equities research analysts clearly believe Medpace is more favorable than Bioanalytical Systems.


This table compares Medpace and Bioanalytical Systems’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Medpace 10.84% 15.86% 8.74%
Bioanalytical Systems 1.06% 4.43% 1.66%

Volatility & Risk

Medpace has a beta of 1.41, suggesting that its stock price is 41% more volatile than the S&P 500. Comparatively, Bioanalytical Systems has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500.

Earnings & Valuation

This table compares Medpace and Bioanalytical Systems’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Medpace $436.15 million 4.53 $39.12 million $1.52 36.47
Bioanalytical Systems $24.24 million 0.62 $880,000.00 N/A N/A

Medpace has higher revenue and earnings than Bioanalytical Systems.

Institutional and Insider Ownership

42.4% of Medpace shares are owned by institutional investors. Comparatively, 7.8% of Bioanalytical Systems shares are owned by institutional investors. 29.5% of Medpace shares are owned by insiders. Comparatively, 1.4% of Bioanalytical Systems shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.


Medpace beats Bioanalytical Systems on 11 of the 11 factors compared between the two stocks.

About Medpace

Medpace Holdings, Inc., a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas. Its clinical development services include medical affairs, clinical trial management, feasibility and start-up study, clinical monitoring, global regulatory affairs, medical writing, biometrics, pharmacovigilance, core laboratory, and quality assurance. Medpace Holdings, Inc. was founded in 1992 and is headquartered in Cincinnati, Ohio.

About Bioanalytical Systems

Bioanalytical Systems, Inc. provides drug discovery and development services, and analytical instruments for pharmaceutical, biotechnology, academic, and government organizations in the United States, rest of North America, the Pacific Rim, Europe, and internationally. It operates through Contract Research Services and Research Products segments. The Contract Research Services segment offers screening and pharmacological testing, preclinical safety testing, formulation development, regulatory compliance, and quality control testing services. It also provides in vivo sampling services for the continuous monitoring of chemical changes in life; preclinical and pathology services; product characterization, method development, and validation; bioanalytical testing to measure drug and metabolite concentrations in complex biological matrices; stability testing to establish and confirm product purity, potency, and shelf life; and climate-controlled archiving services for its customers' data and samples. The Research Products segment offers analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments; and Vetronics' products, such as instruments and related software to monitor and diagnose cardiac function, and measure other vital physiological parameters in cats and dogs in veterinary clinics. Bioanalytical Systems, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with's FREE daily email newsletter.